LEF1 confers resistance to DNA-damaging chemotherapies through upregulation of PARP1 and NUMA1 in ovarian cancer
8.0
来源：
Nature
关键字：
mRNA
发布时间：
2025-09-10 23:41
摘要：
LEF1 has been identified as a key mediator of resistance to DNA-damaging chemotherapy in ovarian cancer. Its upregulation correlates with poor clinical outcomes, while knockdown of LEF1 enhances sensitivity to treatments like Cisplatin and PARP inhibitors. The study suggests that targeting LEF1 could be a promising strategy to improve therapeutic responses in ovarian cancer patients, particularly those with chemoresistant tumors. Additionally, the FDA-approved drug niclosamide shows potential in downregulating LEF1 and enhancing treatment efficacy.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分
business_impact
1.0分
scientific_rigor
1.5分
timeliness_innovation
1.5分
investment_perspective
2.5分
market_value_relevance
1.0分
team_institution_background
0.0分
technical_barrier_competition
0.5分
关键证据
LEF1 is significantly upregulated in chemoresistant ovarian cancer tissues.
LEF1 knockdown increases sensitivity to Cisplatin and PARP inhibitors.
Niclosamide reduces LEF1 levels and enhances chemosensitivity.
真实性检查
否
AI评分总结
LEF1 has been identified as a key mediator of resistance to DNA-damaging chemotherapy in ovarian cancer. Its upregulation correlates with poor clinical outcomes, while knockdown of LEF1 enhances sensitivity to treatments like Cisplatin and PARP inhibitors. The study suggests that targeting LEF1 could be a promising strategy to improve therapeutic responses in ovarian cancer patients, particularly those with chemoresistant tumors. Additionally, the FDA-approved drug niclosamide shows potential in downregulating LEF1 and enhancing treatment efficacy.